|
Gene: UBXN2A |
Gene summary for UBXN2A |
Gene summary. |
Gene information | Species | Human | Gene symbol | UBXN2A | Gene ID | 165324 |
Gene name | UBX domain protein 2A | |
Gene Alias | UBXD4 | |
Cytomap | 2p23.3 | |
Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | P68543 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
165324 | UBXN2A | CCI_1 | Human | Cervix | CC | 5.24e-04 | 8.87e-01 | 0.528 |
165324 | UBXN2A | CCI_2 | Human | Cervix | CC | 8.74e-03 | 5.26e-01 | 0.5249 |
165324 | UBXN2A | LZE2T | Human | Esophagus | ESCC | 6.08e-03 | 4.96e-01 | 0.082 |
165324 | UBXN2A | LZE4T | Human | Esophagus | ESCC | 3.22e-22 | 5.79e-01 | 0.0811 |
165324 | UBXN2A | LZE7T | Human | Esophagus | ESCC | 2.28e-10 | 4.26e-01 | 0.0667 |
165324 | UBXN2A | LZE8T | Human | Esophagus | ESCC | 1.06e-06 | 3.01e-01 | 0.067 |
165324 | UBXN2A | LZE20T | Human | Esophagus | ESCC | 9.74e-05 | 1.64e-01 | 0.0662 |
165324 | UBXN2A | LZE21D1 | Human | Esophagus | HGIN | 3.57e-02 | 3.60e-01 | 0.0632 |
165324 | UBXN2A | LZE22D1 | Human | Esophagus | HGIN | 3.15e-03 | 1.35e-01 | 0.0595 |
165324 | UBXN2A | LZE24T | Human | Esophagus | ESCC | 1.23e-18 | 4.74e-01 | 0.0596 |
165324 | UBXN2A | LZE21T | Human | Esophagus | ESCC | 1.99e-09 | 5.19e-01 | 0.0655 |
165324 | UBXN2A | LZE6T | Human | Esophagus | ESCC | 3.24e-02 | 9.00e-02 | 0.0845 |
165324 | UBXN2A | P1T-E | Human | Esophagus | ESCC | 3.76e-22 | 6.84e-01 | 0.0875 |
165324 | UBXN2A | P2T-E | Human | Esophagus | ESCC | 1.95e-69 | 1.09e+00 | 0.1177 |
165324 | UBXN2A | P4T-E | Human | Esophagus | ESCC | 1.71e-30 | 6.11e-01 | 0.1323 |
165324 | UBXN2A | P5T-E | Human | Esophagus | ESCC | 1.74e-24 | 4.27e-01 | 0.1327 |
165324 | UBXN2A | P8T-E | Human | Esophagus | ESCC | 2.67e-28 | 4.06e-01 | 0.0889 |
165324 | UBXN2A | P9T-E | Human | Esophagus | ESCC | 1.43e-26 | 4.92e-01 | 0.1131 |
165324 | UBXN2A | P10T-E | Human | Esophagus | ESCC | 1.17e-29 | 3.93e-01 | 0.116 |
165324 | UBXN2A | P11T-E | Human | Esophagus | ESCC | 9.25e-27 | 9.26e-01 | 0.1426 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
GO:00162367 | Cervix | CC | macroautophagy | 58/2311 | 291/18723 | 1.40e-04 | 1.70e-03 | 58 |
GO:19908234 | Cervix | CC | response to leukemia inhibitory factor | 22/2311 | 95/18723 | 2.40e-03 | 1.70e-02 | 22 |
GO:00070304 | Cervix | CC | Golgi organization | 32/2311 | 157/18723 | 2.78e-03 | 1.87e-02 | 32 |
GO:19908304 | Cervix | CC | cellular response to leukemia inhibitory factor | 21/2311 | 94/18723 | 4.68e-03 | 2.82e-02 | 21 |
GO:00000452 | Cervix | CC | autophagosome assembly | 21/2311 | 99/18723 | 8.67e-03 | 4.46e-02 | 21 |
GO:004217627 | Esophagus | HGIN | regulation of protein catabolic process | 119/2587 | 391/18723 | 8.09e-18 | 2.43e-15 | 119 |
GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
GO:004316126 | Esophagus | HGIN | proteasome-mediated ubiquitin-dependent protein catabolic process | 114/2587 | 412/18723 | 7.00e-14 | 1.20e-11 | 114 |
GO:190332027 | Esophagus | HGIN | regulation of protein modification by small protein conjugation or removal | 78/2587 | 242/18723 | 1.40e-13 | 2.26e-11 | 78 |
GO:003139627 | Esophagus | HGIN | regulation of protein ubiquitination | 64/2587 | 210/18723 | 3.02e-10 | 2.71e-08 | 64 |
GO:001623616 | Esophagus | HGIN | macroautophagy | 77/2587 | 291/18723 | 7.15e-09 | 4.61e-07 | 77 |
GO:00070336 | Esophagus | HGIN | vacuole organization | 44/2587 | 180/18723 | 8.97e-05 | 1.96e-03 | 44 |
GO:00069975 | Esophagus | HGIN | nucleus organization | 34/2587 | 133/18723 | 2.20e-04 | 4.00e-03 | 34 |
GO:19050375 | Esophagus | HGIN | autophagosome organization | 28/2587 | 103/18723 | 2.58e-04 | 4.53e-03 | 28 |
GO:00000455 | Esophagus | HGIN | autophagosome assembly | 26/2587 | 99/18723 | 7.45e-04 | 9.90e-03 | 26 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0414139 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
hsa04141114 | Esophagus | HGIN | Protein processing in endoplasmic reticulum | 67/1383 | 174/8465 | 1.06e-12 | 2.16e-11 | 1.72e-11 | 67 |
hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa0414114 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
hsa0414115 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0414130 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
hsa04141113 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
hsa0414145 | Oral cavity | EOLP | Protein processing in endoplasmic reticulum | 70/1218 | 174/8465 | 2.84e-17 | 3.06e-15 | 1.81e-15 | 70 |
hsa0414155 | Oral cavity | EOLP | Protein processing in endoplasmic reticulum | 70/1218 | 174/8465 | 2.84e-17 | 3.06e-15 | 1.81e-15 | 70 |
hsa0414162 | Oral cavity | NEOLP | Protein processing in endoplasmic reticulum | 49/1112 | 174/8465 | 9.02e-08 | 1.37e-06 | 8.59e-07 | 49 |
hsa0414172 | Oral cavity | NEOLP | Protein processing in endoplasmic reticulum | 49/1112 | 174/8465 | 9.02e-08 | 1.37e-06 | 8.59e-07 | 49 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UBXN2A | SNV | Missense_Mutation | c.114N>A | p.Asp38Glu | p.D38E | P68543 | protein_coding | tolerated(0.45) | benign(0.031) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
UBXN2A | SNV | Missense_Mutation | c.292N>A | p.Leu98Ile | p.L98I | P68543 | protein_coding | tolerated(0.25) | probably_damaging(0.972) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
UBXN2A | deletion | Frame_Shift_Del | novel | c.371_372delNN | p.Leu124PhefsTer26 | p.L124Ffs*26 | P68543 | protein_coding | TCGA-ET-A40S-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |